C15orf39 Inhibitors
The first six inhibitors, U0126, LY294002, Rapamycin, PD98059, Wortmannin, and SP600125, inhibit the proteins MEK1/2, PI3K, mTOR, MEK, PI3K, and JNK respectively, which are upstream components of these pathways. By inhibiting these upstream components, these inhibitors can indirectly suppress the function of C15orf39 as it is downstream of these proteins in the pathways.
The remaining six inhibitors, SB203580, Akti-1/2, PF-04691502, AZD8055, FR180204, and GSK690693, inhibit p38 MAPK, AKT1/2, PI3K and mTOR, mTOR, ERK, and AKT respectively, which are also essential proteins inthese pathways. Similar to the first six inhibitors, these compounds also decrease the function of C15orf39 indirectly by inhibiting these pathway components. SB203580 and FR180204 particularly inhibit p38 MAPK and ERK, key proteins in the MAPK pathway. By doing so, they affect the downstream signaling events in which C15orf39 is involved, leading to its functional reduction. Likewise, Akti-1/2, PF-04691502, AZD8055, and GSK690693 inhibit AKT1/2, PI3K and mTOR, mTOR, and AKT respectively, which are crucial proteins in the PI3K/AKT/mTOR pathway. Their inhibitory actions on these proteins suppress the downstream signaling involving C15orf39, thereby indirectly reducing its functionality.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphatidylinositol 3-kinase (PI3K), a key player in the PI3K/AKT/mTOR pathway. Its inhibition of PI3K suppresses the subsequent AKT activation, which can lead to an indirect reduction in C15orf39 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a downstream component of the PI3K/AKT/mTOR pathway. The suppression of AKT signaling by this action indirectly reduces the functional activity of C15orf39. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor. Its blockade of ERK activation in the MAPK pathway can lead to an indirect reduction in C15orf39 functionality since ERK promotes downstream signaling events involving C15orf39. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
As a potent PI3K inhibitor, Wortmannin blocks PI3K activity. This inhibition suppresses AKT signaling, which can lead to an indirect reduction of C15orf39 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective JNK inhibitor. By inhibiting JNK activation within the MAPK pathway, downstream signaling events involving C15orf39 can be suppressed, leading to an indirect reduction of C15orf39 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAPK, which is important in the MAPK pathway. This action can lead to the indirect reduction of C15orf39 functional activity. | ||||||
Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 | 612847-09-3 | sc-202048 sc-202048A | 1 mg 5 mg | $208.00 $270.00 | 29 | |
Akti-1/2 inhibits AKT1 and AKT2 in the PI3K/AKT/mTOR pathway. This suppression of AKT signaling can lead to an indirect reduction in C15orf39 activity. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is a potent mTOR inhibitor. Its suppression of the PI3K/AKT/mTOR pathway by inhibiting mTOR can lead to an indirect reduction in C15orf39 function. | ||||||
ERK Inhibitor II, FR180204 | 865362-74-9 | sc-203945 sc-203945A sc-203945B sc-203945C | 1 mg 5 mg 10 mg 50 mg | $110.00 $165.00 $239.00 $942.00 | 45 | |
FR180204 selectively inhibits ERK in the MAPK pathway. This inhibition of ERK can lead to an indirect reduction in C15orf39 functionality. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
GSK690693 is an AKT inhibitor. Its suppression of AKT signaling in the PI3K/AKT/mTOR pathway can lead to an indirect reduction in C15orf39 activity. | ||||||